Advertisement

Elevated MeCP2 in Mice Causes Neurodegeneration Involving Tau Dysregulation and Excitotoxicity: Implications for the Understanding and Treatment of MeCP2 Triplication Syndrome

  • Kristen R. Montgomery
  • A. S. C. Louis Sam Titus
  • Lulu Wang
  • Santosh R. D’Mello
Article
First Online:
Received:
Accepted:

Abstract

Expression of MeCP2 must be carefully regulated as a reduction or increase results in serious neurological disorders. We are studying transgenic mice in which the MeCP2 gene is expressed at about three times higher than the normal level. Male MeCP2-Tg mice, but not female mice, suffer motor and cognitive deficits and die at 18–20 weeks of age. MeCP2-Tg mice display elevated GFAP and Tau expression within the hippocampus and cortex followed by neuronal loss in these brain regions. Loss of Purkinje neurons, but not of granule neurons in the cerebellar cortex is also seen. Exposure of cultured cortical neurons to either conditioned medium from astrocytes (ACM) derived from male MeCP2-Tg mice or normal astrocytes in which MeCP2 is expressed at elevated levels promotes their death. Interestingly, ACM from male, but not female MeCP2-Tg mice, displays this neurotoxicity reflecting the gender selectivity of neurological symptoms in mice. Male ACM, but not female ACM, contains highly elevated levels of glutamate, and its neurotoxicity can be prevented by MK-801, indicating that it is caused by excitotoxicity. Based on the close phenotypic resemblance of MeCP2-Tg mice to patients with MECP2 triplication syndrome, we suggest for the first time that the human syndrome is a neurodegenerative disorder resulting from astrocyte dysfunction that leads to Tau-mediated excitotoxic neurodegeneration. Loss of cortical and hippocampal neurons may explain the mental retardation and epilepsy in patients, whereas ataxia likely results from the loss of Purkinje neurons.

Keywords

MeCP2 triplication syndrome Tau GFAP Astrocyte dysfunction Neurodegeneration 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This research was supported by a grant from the National Institutes of Health (R01 NS040408). We thank Dr. Jade Franklin for making significant contributions to the research and the preparation of figures for the manuscript. We also acknowledge the contribution of Dr. Xiaoju Zou for her assistance with some of the immunohistology work described in the manuscript.

Supplementary material

12035_2018_1046_Fig14_ESM.gif (28 kb)
Supplemental Figure 1

(A and B) Locomotor analysis at 15 weeks of age in WT and MeCP2-Tg female mice (n = 6). (C and D) Forelimb and hindlimb grip strength at 15 weeks of age in WT and MeCP2-Tg female mice (n = 6). (E) Brain Weight of 15-week-old WT and MeCP2-Tg female Mice (n = 6). (F) Body Weight of 15-week-old WT and MeCP2-Tg female mice (n = 6). (GIF 28 kb).

12035_2018_1046_MOESM1_ESM.tif (191 kb)
High Resolution Image (TIFF 191 kb).
12035_2018_1046_Fig15_ESM.gif (15 kb)
Supplemental Figure 2

Male WT and MeCP2-Tg mice (blue), display elevated Tau that correlates to increases in MeCP2 expression (n = 11). Female WT and MeCP2-Tg mice (red) do not display the same correlation (n = 8). (GIF 14 kb).

12035_2018_1046_MOESM2_ESM.tif (165 kb)
High Resolution Image (TIFF 165 kb).

References

  1. 1.
    Adkins NL, Georgel PT (2011) MeCP2: Structure and function. Biochem Cell Biol (Can) 89:1–11CrossRefGoogle Scholar
  2. 2.
    Guy J, Cheval H, Selfridge J, Bird A (2011) The role of MeCP2 in the brain. Annu Rev Cell Dev Biol (U S) 27:631–652CrossRefGoogle Scholar
  3. 3.
    Hite KC, Adams VH, Hansen JC (2009) Recent advances in MeCP2 structure and function. Biochem Cell Biol (Can) 87:219–227CrossRefGoogle Scholar
  4. 4.
    Ausio J, Martinez de Paz A, Esteller M (2014) MeCP2: The long trip from a chromatin protein to neurological disorders. Trends Mol Med (Engl) 20:487–498CrossRefGoogle Scholar
  5. 5.
    Chahrour M, Zoghbi HY (2007) The story of rett syndrome: From clinic to neurobiology. Neuron (U S) 56:422–437CrossRefGoogle Scholar
  6. 6.
    Lombardi LM, Baker SA, Zoghbi HY (2015) MECP2 disorders: From the clinic to mice and back. J Clin Invest (U S) 125:2914–2923CrossRefGoogle Scholar
  7. 7.
    Peters SU, Hundley RJ, Wilson AK, Carvalho CM, Lupski JR, Ramocki MB (2013) Brief report: Regression timing and associated features in MECP2 duplication syndrome. J Autism Dev Disord 43:2484–2490CrossRefPubMedGoogle Scholar
  8. 8.
    Ramocki MB, Tavyev YJ, Peters SU (2010) The MECP2 duplication syndrome. Am J Med Genet A (U S) 152A:1079–1088CrossRefGoogle Scholar
  9. 9.
    Van Esch H (2012) MECP2 duplication syndrome. Mol Syndromol 2:128–136PubMedGoogle Scholar
  10. 10.
    Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR et al (2012a) Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: Implications for transcriptional dysregulation in Huntington disease. Hum Mol Genet (Engl) 21:3097–3111CrossRefGoogle Scholar
  11. 11.
    Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, Raynaud M, Rating D et al (2009) Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet (Engl) 17:444–453CrossRefGoogle Scholar
  12. 12.
    Shimada S, Okamoto N, Ito M, Arai Y, Momosaki K, Togawa M, Maegaki Y, Sugawara M et al (2013) MECP2 duplication syndrome in both genders. Brain Dev (Neth) 35:411–419CrossRefGoogle Scholar
  13. 13.
    Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, Lugtenberg D, Bienvenu T et al (2005) Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet (U S) 77:442–453CrossRefGoogle Scholar
  14. 14.
    Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY (2004) Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet (Engl) 13:2679–2689CrossRefGoogle Scholar
  15. 15.
    Jaworski T, Kugler S, Van Leuven F (2010) Modeling of tau-mediated synaptic and neuronal degeneration in alzheimer's disease. Int J Alzheimers Dis (Engl) 2010:1–10.  https://doi.org/10.4061/2010/573138 CrossRefGoogle Scholar
  16. 16.
    Jaworski T, Dewachter I, Lechat B, Croes S, Termont A, Demedts D, Borghgraef P, Devijver H et al (2009) AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (U S) 4:e7280CrossRefGoogle Scholar
  17. 17.
    Min SW et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med (U S) 21:1154–1162CrossRefGoogle Scholar
  18. 18.
    Wang L, Colodner KJ, Feany MB (2011) Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an alexander disease model. J Neurosci (U S) 31:2868–2877CrossRefGoogle Scholar
  19. 19.
    Bardai FH, Price V, Zaayman M, Wang L, D'Mello SR (2012) Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J Biol Chem (U S) 287:35444–35453Google Scholar
  20. 20.
    Bardai FH, Verma P, Smith C, Rawat V, Wang L, D'Mello SR (2013) Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. J Neurosci (U S) 33:11833–11838Google Scholar
  21. 21.
    Norwood J, Franklin JM, Sharma D, D'Mello SR (2014) Histone deacetylase 3 is necessary for proper brain development. J Biol Chem (U S) 289:34569–34582CrossRefGoogle Scholar
  22. 22.
    Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR (2008) HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol (U S) 68:1076–1092CrossRefGoogle Scholar
  23. 23.
    Chen HM, Wang L, D'Mello SR (2008) A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase. Eur J Neurosci (Fr) 28:2003–2016CrossRefGoogle Scholar
  24. 24.
    Tang SS, Fernandez D, Lazarou LP, Singh R, Fallon P (2012b) MECP2 triplication in 3 brothers - a rarely described cause of familial neurological regression in boys. Eur J Paediatr Neurol (Engl) 16:209–212CrossRefGoogle Scholar
  25. 25.
    Molyneaux BJ, Arlotta P, Menezes JR, Macklis JD (2007) Neuronal subtype specification in the cerebral cortex. Nat Rev Neurosci (Engl) 8:427–437CrossRefGoogle Scholar
  26. 26.
    Cerminara NL, Lang EJ, Sillitoe RV, Apps R (2015) Redefining the cerebellar cortex as an assembly of non-uniform purkinje cell microcircuits. Nat Rev Neurosci (Engl) 16:79–93CrossRefGoogle Scholar
  27. 27.
    Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: Astrocytes in neurodegenerative disease. Nat Clin Pract Neurol (Engl) 2:679–689CrossRefGoogle Scholar
  28. 28.
    Bjornsen LP, Eid T, Holmseth S, Danbolt NC, Spencer DD, de Lanerolle NC (2007) Changes in glial glutamate transporters in human epileptogenic hippocampus: Inadequate explanation for high extracellular glutamate during seizures. Neurobiol Dis (U S) 25:319–330CrossRefGoogle Scholar
  29. 29.
    Robel S, Sontheimer H (2016) Glia as drivers of abnormal neuronal activity. Nat Neurosci (U S) 19:28–33CrossRefGoogle Scholar
  30. 30.
    Delépine C, Nectoux J, Bahi-Buisson N, Chelly J, Bienvenu T (2013) MeCP2 deficiency is associated with impaired microtubule stability. (Germany) FEBS Lett 587:245–253Google Scholar
  31. 31.
    Nectoux J, Florian C, Delepine C, Bahi-Buisson N, Khelfaoui M, Reibel S, Chelly J, Bienvenu T (2012) Altered microtubule dynamics in Mecp2-deficient astrocytes.J Neurosci Res (U S) 90:990–998Google Scholar
  32. 32.
    Papanikolopoulou K, Skoulakis EM (2011) The power and richness of modelling tauopathies in drosophila. Mol Neurobiol (U S) 44:122–133CrossRefGoogle Scholar
  33. 33.
    Sun XY, Tuo QZ, Liuyang ZY, Xie AJ, Feng XL, Yan X, Qiu M, Li S et al (2016) Extrasynaptic NMDA receptor-induced tau overexpression mediates neuronal death through suppressing survival signaling ERK phosphorylation. Cell Death Dis (Engl) 7:e2449CrossRefGoogle Scholar
  34. 34.
    Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB (2001a) Tauopathy in drosophila: Neurodegeneration without neurofibrillary tangles. Science (U S) 293:711–714CrossRefGoogle Scholar
  35. 35.
    Friez MJ, Jones JR, Clarkson K, Lubs H, Abuelo D, Bier JA, Pai S, Simensen R et al (2006) Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics (U S) 118:e1687–e1695Google Scholar
  36. 36.
    Lubs H, Abidi F, Bier JA, Abuelo D, Ouzts L, Voeller K, Fennell E, Stevenson RE et al (1999) XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. Am J Med Genet (U S) 85:243–248CrossRefGoogle Scholar
  37. 37.
    Reardon W, Donoghue V, Murphy AM, King MD, Mayne PD, Horn N, Birk Moller L (2010) Progressive cerebellar degenerative changes in the severe mental retardation syndrome caused by duplication of MECP2 and adjacent loci on Xq28. Eur J Pediatr (Germany) 169:941–949CrossRefGoogle Scholar
  38. 38.
    Jiang M, Ash RT, Baker SA, Suter B, Ferguson A, Park J, Rudy J, Torsky SP et al (2013) Dendritic arborization and spine dynamics are abnormal in the mouse model of MECP2 duplication syndrome. J Neurosci (U S) 33:19518–19533CrossRefGoogle Scholar
  39. 39.
    Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY (2009) Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum Mol Genet (Engl) 18:2431–2442CrossRefGoogle Scholar
  40. 40.
    Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (U S) 320:1224–1229CrossRefGoogle Scholar
  41. 41.
    Samaco RC, Mandel-Brehm C, McGraw CM, Shaw CA, McGill BE, Zoghbi HY (2012) Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nat Genet (U S) 44:206–211CrossRefGoogle Scholar
  42. 42.
    Messing A, Brenner M (2003) Alexander disease: GFAP mutations unify young and old. Lancet Neurol (Engl) 2:75CrossRefGoogle Scholar
  43. 43.
    Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE (2012) Alexander disease. J Neurosci (U S) 32:5017–5023CrossRefGoogle Scholar
  44. 44.
    Yoshida T, Nakagawa M (2012) Clinical aspects and pathology of alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation. Neuropathology (Aust) 32:440–446CrossRefGoogle Scholar
  45. 45.
    Hagemann TL, Connor JX, Messing A (2006) Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J Neurosci (U S) 26:11162–11173CrossRefGoogle Scholar
  46. 46.
    Jany PL, Hagemann TL, Messing A (2013) GFAP expression as an indicator of disease severity in mouse models of alexander disease. ASN Neuro (Engl) 5:e00109Google Scholar
  47. 47.
    Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T, Itohara S, Kato H et al (2007) Murine model of alexander disease: Analysis of GFAP aggregate formation and its pathological significance. Glia (U S) 55:617–631CrossRefGoogle Scholar
  48. 48.
    Minkel HR, Anwer TZ, Arps KM, Brenner M, Olsen ML (2015) Elevated GFAP induces astrocyte dysfunction in caudal brain regions: A potential mechanism for hindbrain involved symptoms in type II alexander disease. Glia (U S) 63:2285–2297CrossRefGoogle Scholar
  49. 49.
    Sosunov AA, Guilfoyle E, Wu X, McKhann GM 2nd, Goldman JE (2013) Phenotypic conversions of “protoplasmic” to “reactive” astrocytes in alexander disease. J Neurosci (U S) 33:7439–7450CrossRefGoogle Scholar
  50. 50.
    Tian R, Wu X, Hagemann TL, Sosunov AA, Messing A, McKhann GM, Goldman JE (2010) Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol (U S) 69:335–345CrossRefGoogle Scholar
  51. 51.
    Ilieva H, Polymenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (U S) 187:761–772CrossRefGoogle Scholar
  52. 52.
    McGann JC, Lioy DT, Mandel G (2012) Astrocytes conspire with neurons during progression of neurological disease. Curr Opin Neurobiol (Engl) 22:850–858CrossRefGoogle Scholar
  53. 53.
    Sun M, Chen L (2015) Studying tauopathies in drosophila: A fruitful model. Exp Neurol 274:52–57CrossRefPubMedGoogle Scholar
  54. 54.
    Boehm J (2013) A ‘danse macabre’: Tau and fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur J Neurosci (Fr) 37:1925–1930CrossRefGoogle Scholar
  55. 55.
    Couratier P, Lesort M, Terro F, Dussartre C, Hugon J (1996) NMDA antagonist blockade of AT8 tau immunoreactive changes in neuronal cultures. Fundam Clin Pharmacol (Engl) 10:344–349CrossRefGoogle Scholar
  56. 56.
    Esclaire F, Lesort M, Blanchard C, Hugon J (1997) Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res (U S) 49:309–318CrossRefGoogle Scholar
  57. 57.
    Sindou P, Couratier P, Barthe D, Hugon J (1992) A dose-dependent increase of tau immunostaining is produced by glutamate toxicity in primary neuronal cultures. Brain Res (Neth) 572:242–246CrossRefGoogle Scholar
  58. 58.
    Pizzi M, Valerio A, Ribola M, Spano PF, Memo M (1993) A tau antisense oligonucleotide decreases neurone sensitivity to excitotoxic injury. Neuroreport (Engl) 4:823–826CrossRefGoogle Scholar
  59. 59.
    Pizzi M, Valerio A, Arrighi V, Galli P, Belloni M, Ribola M, Alberici A, Spano P et al (1995) Inhibition of glutamate-induced neurotoxicity by a tau antisense oligonucleotide in primary culture of rat cerebellar granule cells. Eur J Neurosci (Fr) 7:1603–1613CrossRefGoogle Scholar
  60. 60.
    Cheng JS, Craft R, Yu GQ, Ho K, Wang X, Mohan G, Mangnitsky S, Ponnusamy R et al (2014) Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice. PLoS One (U S) 9:e115765CrossRefGoogle Scholar
  61. 61.
    Ke YD, Suchowerska AK, van der Hoven J, De Silva DM, Wu CW, van Eersel J, Ittner A, Ittner LM (2012) Lessons from tau-deficient mice. Int J Alzheimers Dis (U S) 2012:873270Google Scholar
  62. 62.
    Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron (U S) 70:410–426CrossRefGoogle Scholar
  63. 63.
    Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an alzheimer's disease mouse model. Science (U S) 316:750–754CrossRefGoogle Scholar
  64. 64.
    Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP et al (2011) Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci (U S) 31:1688–1692CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Kristen R. Montgomery
    • 1
  • A. S. C. Louis Sam Titus
    • 1
  • Lulu Wang
    • 1
  • Santosh R. D’Mello
    • 1
  1. 1.Department of Biological SciencesSouthern Methodist UniversityDallasUSA

Personalised recommendations

Cite article

Buy options